Palladon (Hydromorphone Hydrochloride)

Hydromorphone hydrochloride, the active ingredient in Palladon, is an opioid analgesic presented as a strength/form for oral use. It is indicated for management of moderate to severe pain in adult patients when alternative treatments are inadequate. GNH USA supplies Palladon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Palladon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hydromorphone hydrochloride is an opioid that acts on the central nervous system to relieve pain. It is commonly prescribed for: - Acute postoperative pain: Provides rapid relief following surgical procedures. - Cancer‑related pain: Helps control persistent pain associated with malignant disease. - Severe chronic non‑cancer pain: Used when other analgesics are insufficient. - Palliative care pain: Improves comfort in end‑of‑life settings.

Hydromorphone may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects: - Nausea: Feeling of queasiness or urge to vomit. - Constipation: Reduced bowel movements and hard stools. - Drowsiness: Increased sleepiness or fatigue. - Dry mouth: Reduced salivation leading to a parched feeling. - Itching: Mild skin pruritus. - Lightheadedness: Transient dizziness or feeling faint.

Serious or Rare Side Effects: - Respiratory depression: Slowed or shallow breathing that can be fatal. - Severe hypotension: Markedly low blood pressure. - Opioid dependence or addiction: Development of physical or psychological reliance. - Seizures: Uncontrolled electrical activity in the brain. - Anaphylaxis: Acute allergic reaction with airway compromise. - Adrenal insufficiency: Inadequate production of adrenal hormones.

When prescribing Hydromorphone, clinicians should consider several safety measures: - Assess pain severity: Confirm that opioid therapy is appropriate for the level of pain. - Review medical history: Identify respiratory disorders, head injury, or substance‑use disorder. - Monitor for sedation: Observe patients for excessive drowsiness or impaired cognition. - Adjust for renal/hepatic impairment: Dose may need modification in organ dysfunction. - Educate on constipation management: Recommend laxatives or stool softeners. - Store at ambient temperature: Keep below 25°C in the original packaging, protected from moisture.

Hydromorphone can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - CNS depressants: Concurrent use with benzodiazepines or barbiturates can cause profound respiratory depression. - MAO inhibitors: May precipitate severe hypertension or serotonin syndrome. - Potent CYP3A4 inhibitors: Can increase hydromorphone plasma levels, raising overdose risk.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: May worsen constipation. - Diuretics: Can enhance hypotensive effects. - Serotonergic drugs: May increase risk of serotonin syndrome. - Alcohol: Augments central nervous system depression. - QT‑prolonging agents: May contribute to cardiac rhythm disturbances.